Thrombosis Research
Volume 125, Issue 6 , Pages 545-548 , June 2010

A Novel Mutation (G2172→C) in the Factor V Gene in a Chinese Family with Hereditary Activated Protein C Resistance

  • Huacong Cai

      Affiliations

    • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
  • ,
  • Baolai Hua

      Affiliations

    • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
  • ,
  • Liankai Fan

      Affiliations

    • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
  • ,
  • Qian Wang

      Affiliations

    • Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
  • ,
  • Shujie Wang

      Affiliations

    • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
  • ,
  • Yongqiang Zhao

      Affiliations

    • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China
    • Corresponding Author InformationCorresponding author. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, 1 Shuaifuyuan, Beijing, 100730, China. Tel.:+86 10 65295020; fax: +86 10 88068271.

Received 26 June 2009 ,Revised 4 February 2010 ,Accepted 16 February 2010.

References 

  1. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743–4746
  2. Amer L, Kisiel W, Searles R, Williams RJ. Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res. 1990;57:247–258
  3. Dahlbäck B, Carlsson M, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004–1008
  4. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536–1538
  5. Bertina R, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, Ronde Hd, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
  6. Greengard J, Sun X, Xu X, Fernandez J, Griffin J, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994;343:1361–1362
  7. Mary C, W TA , H WR , R HS , D RW , Paul E, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19–25
  8. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 2002;99:2720–2725
  9. Marchiori A, Mosena L, Prins M, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica. 2007;92:1107–1114
  10. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2, 132 consecutive unselected patients with venous thromboembolism–results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77:444–451
  11. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab. 2005;86:91–99
  12. Bai C, Pan J, Li X. Factor V Leiden and PTG20210A gene mutation in patients with venous thrombosis and healthy blood donors. Zhonghua Yi Xue Za Zhi. 1999;79:900–902
  13. Han X, Ren J, Hao B, Cao W, Liu X, Hou L, et al. Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15:612–616
  14. Jun Z, Ping T, Lei Y, Li L, Ming S, Jing W. Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin Lab Haematol. 2006;28:111–116
  15. Wu J, Gu J, Xu J, Wang J, Sun Z, Smirnov M, et al. Factor V Leiden mutation in one family of Chinese origin. Chin Med J (Engl). 2001;114:379–381
  16. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood. 1998;91:1140–1144
  17. Jenny RJ, Pittman DD, JToole J, Kriz RW, Aldape RA, Hewick RM, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A. 1987;84:4846–4850
  18. Segers K, Dahlbäck B, Nicolaes G. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007;98:530–542
  19. Castoldi E, Rosing J. Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol. 2004;11:176–181
  20. Chan W, Lee C, Kwong Y, Lam C, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998;91:1135–1139
  21. Castoldi E, Brugge J, Nicolaes G, Girelli D, Tans G, Rosing J. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood. 2004;103:4173–4179
  22. Norstrom E, Thorelli E, Dahlbäck B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002;100:524–530
  23. Zhao Y, Wang X, Ding Q, Wei X, Zhu T, Kaguelidou Florentia, et al. Antithrombin, Protein C, Protein S and Activated Protein C Resistance in the General Healthy Chinese Population: Normal Plasmatic Ranges and Genetic Defects. Blood. 2007;110:63B;Abstract

PII: S0049-3848(10)00147-7

doi: 10.1016/j.thromres.2010.02.009

Thrombosis Research
Volume 125, Issue 6 , Pages 545-548 , June 2010